Trials / Unknown
UnknownNCT05123209
Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients With Advanced Liver Tumors
Safety and Efficacy Evaluation of IM83 CAR-T Cells for Patients Wirh Advanced Liver Tumors
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Beijing Immunochina Medical Science & Technology Co., Ltd. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a open-label, single center, cohort study to determine the efficacy and safety of IM83 CAR-T cells in patients with advanced Liver Tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | IM83 CAR-T cells | 3×10\^9 CAR-T cells |
| COMBINATION_PRODUCT | The second-line treatment of liver cancer | approved by NMPA |
Timeline
- Start date
- 2021-08-24
- Primary completion
- 2023-08-30
- Completion
- 2023-08-30
- First posted
- 2021-11-17
- Last updated
- 2021-11-17
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05123209. Inclusion in this directory is not an endorsement.